论文部分内容阅读
自1972年第一家生物技术公司诞生以来,其主要的运作模式是与大型制药企业通过“付费-服务”方式进行合作。现在,生物技术公司不再是制药企业无力的合作者,而是具有无限潜力和机会的实体。促进生物技术产业迅速发展的重要因素之一是美国、欧洲和日本制定的“罕见药”政策。重组蛋白质主导着生物药品市场;单克隆抗体作为商业生物药品中最有活力的部分,已充满了研究与开发管线,其研发和上市将步入快车道。2002年生物药品的上市申请将会更多。
Since the birth of the first biotechnology company in 1972, its main mode of operation has been to cooperate with large pharmaceutical companies through the “pay-for-service” approach. Now, biotechnology companies are no longer the incompetent partners of pharmaceutical companies, but entities with unlimited potential and opportunities. One of the important factors to promote the rapid development of the biotechnology industry is the “rare drug” policy formulated by the United States, Europe and Japan. Recombinant proteins dominate the biopharmaceutical market; as the most dynamic part of commercial biopharmaceuticals, monoclonal antibodies are already full of research and development pipelines, and their R&D and listing will enter the fast lane. There will be more applications for biopharmaceuticals in 2002.